Dr Reddy’s, Alvotech to co-develop Keytruda biosimilar

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Iu2xyot
via IFTTT